Non-fatal major cardiovascular events associated with androgen receptor pathway inhibitors in prostate cancer: systematic review and network meta-analysis
Clicks: 1
ID: 323508
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #274 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Importance Major cardiovascular events (MACE) cause substantial morbidity and mortality in patients with prostate cancer (PC). Androgen receptor pathway inhibitors (ARPIs) are associated with cardiovascular toxicity, yet comparative data on the risk of MACE are lacking. Objective To evaluate the risk of non-fatal MACE among abiraterone, apalutamide, darolutamide, and enzalutamide users, in patients with localized or metastatic PC. Methods We conducted a Systematic search of Medline, Cochrane, and ClinicalTrials.gov through June 2025. Randomized controlled trials (RCTs) reporting cardiovascular events with ARPI monotherapy or combination therapy were eligible. Data on study design, patient characteristics and cardiovascular events were extracted. Network meta-analysis (NMA) was conducted using frequentist and Bayesian approaches, with surface under the cumulative ranking curve (SUCRA) for ARPI comparisons. The primary endpoint was the risk of non-fatal MACE (myocardial infarction, ischemic stroke or heart failure). Secondary outcomes were myocardial infarction, ischemic stroke, heart failure, and other cardiovascular events. Results Thirty-nine trials including 22,717 patients were analyzed. SUCRA rankings showed that apalutamide and enzalutamide had the highest probability of non-fatal MACE (0.18 and 0.23 respectively, with lower ranks indicating higher probability), whereas control arms and darolutamide had the lowest (0.93 and 0.59 respectively). Apalutamide (OR 2.53, 95% CI [1.22;5.26]), enzalutamide (OR 2.30, 95% CI [1.61;3.28]), and abiraterone (OR 2.06, 95% CI [1.29;3.28]) but not darolutamide (OR 1.39, 95% CI [0.77;2.51]) were associated with a significantly higher risk of non-fatal MACE compared with control. Heterogeneity was low (I² = 25.1%) and no network inconsistency was detected (p = 0.665). Conclusion And Relevance Apalutamide and enzalutamide carry higher risk of non-fatal MACE, whereas darolutamide shows the lowest risk, supporting its preferential use in patients with elevated cardiovascular risk.
| Reference Key |
openalex_W7172332711
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | C Dolladille, L Durand, A Da Silva, J Alexandre, F Minoc |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.156
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.